Company Overview and News

3
FMCG stocks: MNC players beat domestic peers on returns front

2018-06-04 thehindubusinessline
Priya Kansara FMCG stocks have been giving robust returns in the last decade with their market capitalisation (₹1,000 crore and above) jumping seven-fold, according to data provided by Capitaline. This has been led by MNC stocks, which have done better than domestic FMCG companies, with market-cap jumping 6.5 times and six times, respectively.
500825 DABUR BRTQY GSKCONS NESTLEIND HINDUNILVR DBRQY 532424 GDRJY 500096 507815 GILLETTE 500696 GODREJCP 500676 500790 BRITANNIA NSZTY

3
Podcast |The Business of The Family - The Wadia#39;s

2018-05-21 moneycontrol
Over the past few months, we have been revisiting the origins of some of the most illustrious empires in India and retracing their family trees.
500825 BRTQY BRITANNIA

3
Britannia Industries Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500825 BRTQY BRITANNIA

6
Britannia Industries re-appoints Varun Berry as MD for five years

2018-05-16 livemint
Bengaluru: Biscuits maker Britannia Industries Ltd Wednesday said its board has re-appointed Varun Berry as managing director for five years, subject to approval by its shareholders.
500825 PEP BRTQY BRITANNIA

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to NSE:BRITANNIA / BRITANNIA INDUSTRIES LTD. on message board site Silicon Investor.

BRITANNIA GOLD CORP - V.BGP BRITANNIA GOLD BGP-V